Gyre Therapeutics Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
618
- Stock Symbol
-
GYRE
- Investments
-
4
- Share Price
-
$4.21
- (As of Friday Closing)
Gyre Therapeutics General Information
Description
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Contact Information
Website
www.gyretx.comCorporate Office
- 12730 High Bluff Drive
- Suite 250
- San Diego, CA 92130
- United States
Corporate Office
- 12730 High Bluff Drive
- Suite 250
- San Diego, CA 92130
- United States
Gyre Therapeutics Stock Performance
As of 20-Nov-2026, Gyre Therapeutics’s stock price is $4.21. Its current market cap is $461M with 109M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.21 | $4.52 | $3.97 - $9.14 | $461M | 109M | 179K | -$0.31 |
Gyre Therapeutics Financials Summary
As of 30-Sep-2026, Gyre Therapeutics has a trailing 12-month revenue of $110M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 762,840 | 656,723 | 1,050,447 | 1,941,033 |
| Revenue | 110,058 | 116,588 | 105,757 | 113,450 |
| EBITDA | (24,855) | 15,209 | 23,259 | (76,895) |
| Net Income | (29,008) | 5,027 | 12,085 | (92,933) |
| Total Assets | 201,251 | 166,132 | 125,406 | 116,539 |
| Total Debt | 3,010 | 939 | 1,598 | 409 |
Gyre Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Gyre Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Gyre Therapeutics Comparisons
Industry
Financing
Details
Gyre Therapeutics Competitors (82)
One of Gyre Therapeutics’s 82 competitors is ADC Therapeutics, a Formerly VC-backed company based in Epalinges, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ADC Therapeutics | Formerly VC-backed | Epalinges, Switzerland | ||||
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Innate Pharma | Formerly VC-backed | Marseille, France | ||||
| Moderna | Formerly VC-backed | Cambridge, MA |
Gyre Therapeutics Signals
Gyre Therapeutics Investments & Acquisitions (4)
Gyre Therapeutics’s most recent deal was a Merger/Acquisition with Cullgen for . The deal was made on 04-May-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cullgen | 04-May-2026 | Merger/Acquisition | Drug Discovery | ||
| Beijing Continent | 30-Oct-2023 | Merger/Acquisition | Drug Discovery | ||
| GNI Group (F351 Program) | 15-Feb-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Targacept | 20-Aug-2015 | Merger/Acquisition | Biotechnology |
Gyre Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Gyre Therapeutics Exits (1)
Gyre Therapeutics’s most recent exit was on 30-Oct-2023 from Beijing Continent. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Beijing Continent | 30-Oct-2023 | Completed |
|
Gyre Therapeutics Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cullgen | San Diego, CA | 2018 | |
| Beijing Continent | Beijing, China | 2002 |
Gyre Therapeutics FAQs
-
When was Gyre Therapeutics founded?
Gyre Therapeutics was founded in 1997.
-
Where is Gyre Therapeutics headquartered?
Gyre Therapeutics is headquartered in San Diego, CA.
-
What is the size of Gyre Therapeutics?
Gyre Therapeutics has 618 total employees.
-
What industry is Gyre Therapeutics in?
Gyre Therapeutics’s primary industry is Drug Discovery.
-
Is Gyre Therapeutics a private or public company?
Gyre Therapeutics is a Public company.
-
What is Gyre Therapeutics’s stock symbol?
The ticker symbol for Gyre Therapeutics is GYRE.
-
What is the current stock price of Gyre Therapeutics?
As of 20-Nov-2026 the stock price of Gyre Therapeutics is $4.21.
-
What is the current market cap of Gyre Therapeutics?
The current market capitalization of Gyre Therapeutics is $461M.
-
What is Gyre Therapeutics’s current revenue?
The trailing twelve month revenue for Gyre Therapeutics is $110M.
-
Who are Gyre Therapeutics’s competitors?
ADC Therapeutics, Blueprint Medicines, Gilead, Innate Pharma, and Moderna are some of the 82 competitors of Gyre Therapeutics.
-
What is Gyre Therapeutics’s annual earnings per share (EPS)?
Gyre Therapeutics’s EPS for 12 months was -$0.31.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process